High dietary levels of momfluorothrin, a nongenotoxic synthetic pyrethroid, induced hepatocellular tumors in male and female Wistar rats in a 2-year bioassay. The mode of action (MOA) for rat hepatocellular tumors was postulated to occur via activation of the constitutive androstane receptor (CAR), as momfluorothrin is a close structural analogue of the pyrethroid metofluthrin, which is known to produce rat liver tumors through a CAR-mediated MOA. To elucidate the MOA for rat hepatocellular tumor formation by momfluorothrin, this study was conducted to examine effects on key and associative events of the CAR-mediated MOA for phenobarbital based on the International Programme on Chemical Safety framework. A 2-week in vivo study in Wistar rats revealed that momfluorothrin induced CYP2B activities, increased liver weights, produced hepatocyte hypertrophy and increased hepatocyte replicative DNA synthesis. These effects correlated with the dose-response relationship for liver tumor formation and also showed reversibility upon cessation of treatment. Moreover, momfluorothrin did not increase CYP2B1/2 mRNA expression and hepatocyte replicative DNA synthesis in CAR knockout rats. Using cultured Wistar rat hepatocytes and the RNA interference technique, knockdown of CAR resulted in a suppression of induction of CYP2B1/2 mRNA levels by momfluorothrin. Alternative MOAs for liver tumor formation were excluded. A global gene expression profile analysis of the liver of male Wistar rats treated with momfluorothrin for 2 weeks also showed similarity to the prototypic CAR activator phenobarbital. Overall, these data strongly support that the postulated MOA for momfluorothrin-induced rat hepatocellular tumors as being mediated by CAR activation.
In recent years, frameworks for analysing the modes of action (MOAs) by which chemicals produce tumors in rodents and the relevance of such tumor data for human risk have been developed through the International Life Sciences Institute (Cohen et al., 2004; Meek et al., 2003; Seed et al., 2005) and the International Programme on Chemical Safety (IPCS) (Boobis et al., , 2008 Sonich-Mullin et al., 2001) . Epsilon-Momfluorothrin (CAS No. 1065124-65-3; 2,3,5,6-Tetrafluoro-4-(methoxymethyl) benzyl(Z)-(1R,3R)-3-(2-cyanoprop-1-enyl)-2,2-dimethylcyclopropanecarboxylate, referred to as momfluorothrin in this article) was developed as a Type I synthetic pyrethroid insecticide consisting of 2 main isomers (RTZ: RTE ratio is 9:1) for use to treat crawling insects in both indoor residential settings and outdoor commercial/residential/barn settings. In a 2-year bioassay using male and female Wistar rats fed diet containing momfluorothrin at 0, 200, 500, 1500, and 3000 ppm, the incidence of hepatocellular tumors (adenomas, carcinomas, or combined adenomas and carcinomas) was increased at 1500 ppm in males and at 3000 ppm in males and females (Table 1) (ECHA, 2014) . In contrast, momfluorothrin was not tumorigenic in the liver or any other tissue in male or female CD-1 mice when administered at dietary levels of 600, 2500, and 5500 ppm (ECHA, 2014) . This rat specific tumorigenicity was consistent with other pyrethroids such as metofluthrin ) and the natural pyrethrins (Osimitz and Lake, 2009) .
Momfluorothrin is a close structural analogue of the type I pyrethroid insecticide metofluthrin. The metofluthrin MOA analysis had been conducted based on the IPCS framework . High doses of metofluthrin have also been shown to produce hepatocellular tumors in rats, and in vivo and in vitro MOA studies have demonstrated that metofluthrin induces hepatic microsomal cytochrome P450 (CYP) 2B enzymes and hepatocellular replicative DNA synthesis in rats, suggesting that the MOA for rat liver tumor formation by metofluthrin is similar to that of other rodent nongenotoxic hepatocarcinogens that are constitutive androstane receptor (CAR) activators Hirose et al., 2009; Kushida et al., 2016; Yamada et al., 2009 Yamada et al., , 2015 such as sodium phenobarbital (sodium phenobarbitone; NaPB) Rossi et al., 1977) . Thus, the MOA for momfluorothrin-induced rat hepatocellular tumors is also predicted to be the CAR-mediated MOA as it is for metofluthrin.
To determine whether this postulated MOA for momfluorothrin-induced hepatocellular tumors in rats is correct, in vivo and in vitro experiments were conducted also based on the IPCS framework. If a key event (or events) is an essential element for carcinogenesis, it must precede the appearance of the tumors (Cohen and Arnold, 2016) . Therefore, the MOA data at an early phase of treatment was collected in these studies to support the following key (1) and associative (2) events in the etiology of the rodent liver tumors: (1) CAR nuclear receptor activation and hepatocellular proliferation; and (2) CYP2B induction and liver hypertrophy (both morphological changes and increases in liver weight) . Based on the IPCS framework (Boobis et al., , 2008 Cohen et al., 2004; Meek et al., 2003; Sonich-Mullin et al., 2001) utilizing the data obtained in these studies and existing data from previous studies, the postulated rat MOA was evaluated against the modified Bradford Hill considerations Sonich-Mullin et al., 2001) to satisfy the conditions of dose and temporal concordance, biological plausibility, coherence, strength, consistency, and specificity for a CAR-mediated MOA while excluding other alternative MOAs.
Recently developed genomics technology has the potential to improve our understanding of an organism's response to stressors, and there is general agreement that toxicogenomics will play an increasing role in regulatory decision-making (Boverhof and Zacharewski, 2006) . We believe that global gene expression analysis may provide useful information for evaluation of MOA as a preliminary screening tool Yamada et al., 2005 Yamada et al., , 2014 . To determine the global gene expression profile and similarity to the known MOAs for liver tumor production, liver samples in the toxicity screening study conducted at the early stage of development of this chemical were subjected to this analysis although sampling conditions were different from that in the present MOA studies, and the data presented in this article. The findings from global gene expression analysis strongly support our postulated MOA based on the MOA analysis for momfluorothrin-induced liver tumor production in this study.
MATERIALS AND METHODS
Chemicals. Test chemicals were obtained from the following manufacturers: epsilon-momfluorothrin (Lot no. 9CM0109G; purity 95.7%; storage condition, cold storage) and epsilon-metofluthrin (Lot no.100702; purity 98.8%; storage condition, cold storage; referred to as metofluthrin in this article) were provided by Sumitomo Chemical Co., Ltd. (Tokyo, Japan); phenobarbital-Na (NaPB; Lot no.AWJ4960; purity 98.0%; storage condition, room temperature) was purchased from Wako Pure Chemical Industries, Ltd. (Osaka, Japan).
Animals and husbandry.
All experiments were performed in accordance with The Guide for Animal Care and Use of Sumitomo Chemical Co., Ltd.
HarlanRccHanTM:WIST (Wistar strain) rats aged 9 weeks were purchased from Japan Laboratory Animals, Inc., Hanno Breeding Center (Saitama, Japan) as this was the strain of rats used in the 2-year cancer bioassay. In addition, CAR Knockout (KO) rats with a Crl:CD (SD) genetic background aged 10 weeks and wild-type Crl:CD (SD) rats (WT) aged 11 weeks were purchased from SAGE labs, Inc. (Boyertown, Pennsylvania, 19512, USA) and Charles River Japan, Inc., Hino Breeding Center (Shiga, Japan), respectively. SD genetic background CAR KO rats were used as Wistar background KO rats were not available. Similar responses to momfluorothrin in the liver of WT rats of both strains were observed in this study (described later). Prior to the MOA analysis, BrlHan:WIST@Jcl(GALAS) (Wistar strain) rats aged 4 weeks were purchased from CLEA Japan, Inc., Fuji Breeding Center (Shizuoka, Japan) and used in the toxicity screening study at the early stage of development of this chemical; liver samples from the BrlHan:WIST@Jcl(GALAS) rats were subjected to the global gene expression profile analysis and the data are presented in this article.
Animals were acclimatized to laboratory conditions for 7 days prior to treatment in the in vivo assay. During the course of the study, the environmental conditions in the animal room were set to maintain a temperature range of 22-26 C and a relative humidity range of 40-70%, with frequent ventilation (more than 10 times per hour) and a 12-h light (8:00-20:00)/12-h dark (20:00-8:00) illumination cycle. A commercially available pulverized diet (CRF-1; Oriental Yeast Co., Ltd, Tokyo) and filtered tap water were provided ad libitum throughout the study. The animals were not fasted overnight prior to sacrifice in the present MOA studies, but they were fasted in the toxicity screening study.
Design for in vivo studies: MOA analysis using Wistar rats. In this MOA study, 3 different experiments were conducted for evaluating time-course, dose-dependency, and reversibility. Male and female rats (10 animals/dose/sex) fed diets containing momfluorothrin at 0 (control) and 3000 ppm (the highest dose in the 2-year bioassay, a tumor inducing dose level) for 7 and 14 days to evaluate the time-course of changes. For evaluation of the dose-dependency, momfluorothrin was administered at 0, 200, 500, 1500, and 3000 ppm to both sexes (10 animals/dose/sex) for 7 days; these levels were consistent with those of the 2-year bioassay. Furthermore, the reversibility of hepatic effects was evaluated in male rats (10 animals/dose) by cessation of treatment for 7 days after 7-days treatment with momfluorothrin at 0 and 3000 ppm.
Design for in vivo studies: MOA analysis using CAR KO rats. Male WT Crl:CD (SD) and CAR KO rats (5 animals/group, respectively) were fed diets containing momfluorothrin at 0 or 3000 ppm for 7 days to clarify whether the hepatocellular proliferation involved CAR activation. As shown below, since momfluorothrin treatment at 3000 ppm for 7 days significantly increased CYP2B activity, liver weight and replicative DNA synthesis in male Wistar rats, the same treatment time was selected for this experiment. This model has been quite recently developed and only limited data have been published (Chamberlain et al., 2014) . Thus, 2 additional CAR-mediated MOA liver tumor inducers NaPB (1000 ppm) (Rossi et al., 1977) and metofluthrin (1800 ppm) were examined in this study to confirm reliability of the CAR KO rat model. Administration of PB in drinking water (500 ppm, the corresponding daily intake was of 39.5 mg/kg/d in males and of 46.7 mg/kg/d in females) caused liver adenomas in male and female Wistar rats (Rossi et al., 1977) . In our study, treatment of 1000 ppm NaPB in diet revealed a similar range of daily intake (approximately 50 mg/kg/d, shown in Table 3 ).
Although we consider that 8-10 rats per group is preferred for reliable evaluation of BrdU labeling under the study conditions we used, due to limitation of the number of the CAR KO rat availability, 5 animals per group were used in the present study. Since small numbers of animals were used (5 rats/group), to observe any expected CAR-mediated alterations (even a tendency) in the WT animals, 2 sets of experiments (5 rats/group in each experiment) were conducted in the WT rats.
Observations and tissue sampling. Mortality, body weights, and food consumption were monitored throughout the studies. For evaluation of replicative DNA synthesis, Alzet minipumps (Model 2ML1; Alzet Corporation, Palo Alto, California, USA) containing 5-bromo-2 0 -deoxy-uridine (BrdU; a structural analog of thymidine that incorporates into nuclear DNA and is used as a surrogate marker of cell proliferation (Wood et al., 2015) , Sigma Company, St Louis, Missouri, USA) with a release rate of 200 lg/h, were implanted in the subcutaneous tissue of rats under isoflurane anesthesia on the day prior to 4 days of the scheduled euthanization to avoid the effects of a palatability problem at the early phase of the study. After 7-or 14-day treatment period, rats were sacrificed under deep anesthesia by isoflurane without prior fasting on the morning of Day 8 or 15, and then livers were excised quickly and weighed. Some liver tissue was stored in RNA stabilization solution (Ambion, Austin, Texas, USA) at À80 C until analyzed for gene expression. The remaining liver tissue was processed for hepatic microsomal CYP enzyme activity analysis, histopathology, and cell proliferation measurement.
Liver histopathology. Segments of livers from all surviving animals were fixed in buffered 4% paraformaldehyde or 10% neutral buffered formalin, embedded in paraffin, sectioned, stained with hematoxylin and eosin, and examined by light microscopy.
In addition, the left lateral lobe in the control and treatment groups was prefixed by perfusing 2.5% glutaraldehyde in 0.2 M phosphate buffer (pH 7.4) using a syringe for 2 animals/group in Wistar rats. The sample blocks were postfixed in 2% osmium tetroxide, dehydrated, and embedded in epoxy resin. Ultra-thin sections were prepared, stained with uranyl acetate and lead citrate, and examined by JEM-1400 transmission electron microscopy (JEOL, Tokyo, Japan).
Hepatocyte replicative DNA synthesis from BrdU-labeling indices. Hepatocyte replicative DNA synthesis was determined in the livers from all surviving animals by an immunohistochemical method using BrdU monoclonal antibody Yamada et al., 2014) . BrdU labeling was analyzed microscopically in a blinded manner with more than 2000 hepatocytes per rat being evaluated. A small section of duodenum from each animal was also processed to serve as a control for confirming systemic availability of BrdU and immunohistochemical staining.
Quantitative real-time polymerase chain reaction of the selected genes. Using liver samples from male Wistar rats treated with momfluorothrin at 3000 ppm for 7 and 14 days, hepatic CYP1A2, CYP2B1/2, CYP3A1, CYP3A2, and CYP4A1 mRNA expression levels were analyzed by quantitative real-time polymerase chain reaction (PCR). Hepatic CYP2B1/2 and CAR mRNA levels and CYP2B1/2 mRNA levels were also analyzed in samples from the in vitro RNA interference (RNAi) experiment using rat hepatocytes and in in vivo study of CAR KO rats, respectively. Total RNA preparation and quantitative real-time PCR were conducted as previously described in Yamada et al. (2014) . The primer and probe sets are shown in Supplementary Table 1 .
Hepatic microsomal CYP enzyme activity. Hepatic microsomal CYP enzyme activity was determined in selected liver samples such as from the dose-response study. Liver postmitochondrial supernatant (S9) fractions were prepared and CYP2B activity was determined as 7-pentoxyresorufin O-depentylase (PROD) by fluorometric analysis using the specific substrate for CYP2B enzyme as shown previously in Yamada et al. (2014) .
Evaluation for CAR involvement on the MOA for CYP2B1/2 mRNA induction in cultured rat hepatocytes using the RNAi technique. The assay was basically conducted as previously described in Deguchi et al. (2009 Following the transfection (on Day 1), hepatocytes were treated with 50 lM of NaPB and 100 lM of momfluorothrin in medium for 2 days. A concentration of 50 lM of NaPB was selected as this concentration has previously been shown to induce CYP2B-dependent enzyme activity in cultured rat hepatocytes Hirose et al., 2009) . Medium was changed on a daily basis thereafter. The control group was treated in the same manner without test chemical. The experiment was examined using 3 wells for each group. On Day 3, hepatocytes were washed with phosphate-buffered saline and the total RNA was extracted using Isogen (Nippon Gene, Japan). During the experiment, no cytotoxicity was observed visually and there were no changes in expression levels of the housekeeping gene (glyceraldehyde-3-phosphate dehydrogenase) and CYP4A mRNA (data not shown).
Global gene expression analysis. Since detailed MOA for momfluorothrin-induced liver tumor production was evaluated for the key and associate evens in the current MOA studies, the additional data of global gene expression analysis in the general toxicity study of momfluorothrin may not be essential for prediction of the MOA for momfluorothrin-induced liver tumor production. However, in the general toxicity studies, animals are usually fasted prior to euthanization to avoid confounding by possible variation of food consumption. In contrast, since it is well known that fasting alters the CYP profile affecting drug/chemical metabolism (Maronpot et al., 2010; Sohn and Fiala, 1995) , the data of global gene expression analysis in the general toxicity study with fasting may provide valuable information for considering newly postulated MOA of other compounds at the point of departure of the MOA study. The analysis was determined in livers from male BrlHan:WIST@Jcl(GALAS) rats (4 animals per groups) treated with momfluorothrin at 0 and 3000 ppm for 2 weeks; the animals were treated under the same conditions as in the MOA studies described earlier, excepting for fasting prior to euthanization. Details of the analytical methods are shown in Supplementary material. The gene expression data can be downloaded from the National Center for Biotechnology Information Gene Expression Omnibus (Accession No. GSE94738; http://www.ncbi.nlm.nih.gov/geo/info/ linking.html.). The obtained gene expression data were subjected to hierarchical clustering analysis with GeneSpring GX 13.1 software (Agilent Technologies, Santa Clara, California.). Clustering was conducted with the probe sets, whose expression was known to be changed in our reference data; carbon tetrachloride (CCl 4 ) and thioacetamide as cytotoxic compounds (Abe et al., 2014; Manibusan et al., 2007) , clofibrate as a peroxisome proliferatoractivated receptor alpha (PPARa) activator (Corton et al., 2014) , and NaPB as a CAR activator for 2 weeks.
Statistical analysis. For comparison among multiple groups, if the variables exhibited a normal distribution by the Bartlett-test, the Dunnett-test was applied for a comparison of the treated groups with the control group. The Steel-test was applied instead of the Dunnett-test when the data did not exhibit a normal distribution. For comparison between 2 groups, the F test was applied to compare treated groups with the control group. If the variance was homogeneous, Student's t test was used. If the variance was heterogeneous, the Aspin-Welch-test was used. Two-tailed tests were employed for evaluation except for BrdU labeling index and BrdU labeling index was evaluated by 1-tail test with P .05 and .01 as the levels of significance.
RESULTS

Analysis for Selected Hepatic CYP mRNA Levels
In the MOA studies, the effect of momfluorothrin on some selected CYP mRNA levels were determined in the livers of male Wistar rats treated with momfluorothrin at 3000 ppm for 7-and 14 days (Figure 1 ). Although hepatic CYP2B1/2 mRNA levels were significantly increased after 7-and 14-day treatment (18-and 16-fold, respectively), CYP3A1 and CYP4A1 mRNA levels were only marginally increased after 7-or 14-day treatment (<1.5-fold). No significant changes were observed in CYP1A2 and CYP3A2 mRNA levels. These findings suggested that momfluorothrin activates CAR but not either the aryl hydrocarbon receptor (AhR) or PPARa.
Evaluation of CAR Involvement in CYP2B Induction in Cultured Rat Hepatocytes Using the RNAi Technique
To confirm whether hepatic CYP2B induction (ie, CYP2B1/2 mRNA) by momfluorothrin involves CAR activation, the effect of CAR knockdown by the RNAi technique on CYP2B induction by momfluorothrin was investigated in a rat cultured hepatocyte system. A concentration range finding experiment with 5-1000 lM momfluorothrin demonstrated that CYP2B1/2 mRNA was significantly increased at 100 lM and higher concentrations with the peak effect being observed at 100 lM (2.6-fold of control) ( Figure 2A ). Subsequent experiments were performed with 100 lM momfluorothrin.
When rat hepatocytes were treated with CAR-siRNA together with either 50 lM NaPB or 100 lM momfluorothrin, expression levels of CAR mRNA were significantly suppressed by 80% and 81% of each negative CAR-siRNA control (NC) in NaPB and momfluorothrin treated groups, respectively (Figs. 2B and C). Under the CAR-suppressed condition, expression levels of CYP2B1/2 mRNA in NaPB and momfluorothrin-treated groups were also reduced, respectively, by 67% (close to statistical significance, P ¼ .070) and 68% (close to statistical significance, P ¼ .067) compared with each NC (Figs. 2D and E). These data demonstrate that CAR mediates CYP2B induction by both NaPB and momfluorothrin.
In Vivo Momfluorothrin Time-Course Study in Wistar Rats
To investigate the time course of momfluorothrin-induced hepatic effects, male and female rats were treated with 0 (control) and 3000 ppm momfluorothrin for 7 and 14 days. The data from this in vivo study are summarized in Table 2 . There were no severe toxicities such as death or marked suppression of body weight and food consumption up to 14 days. As shown in Figure 3A , relative liver weights were significantly increased to a similar extent in both sexes after 7 and 14 days treatment. Although replicative DNA synthesis was also significantly increased after 7-and 14-days treatment in both sexes, the increase in replicative DNA synthesis was less marked after 14 days than after 7 days in both sexes ( Figure 3B ). For part A, values significantly different from control are: *P < .05; **P < .01. For parts B-E, values significantly different between untreated and NC treated hepatocytes are *P < .05 and between NC and either 50 lM NaPB or 100 lM momfluorothrin are ## P < .01.
In Vivo Momfluorothrin Dose-Dependency and Reversibility Study in Wistar Rats
Male and female Wistar rats were treated with 0 (control), 200, 500, 1500, and 3000 ppm momfluorothrin for 7 days. The selected data are presented in Table 2 . Significant decreased body weight gains were observed at 1500 and 3000 ppm on Day 3 due to palatability problems, however, these recovered to control levels by the end of the treatment period. At the 2 highest momfluorothrin dose levels (1500 and 3000 ppm), relative liver weight ( Figure 4A ) and replicative DNA synthesis ( Figure 4B ) were significantly increased in both male and female rats. A small nondose-dependent increase in animals with the lesion/total number of animals examined. Values significantly different from control (0 ppm) are: *P < .05; **p < .01. Values within shaded areas indicate toxicologically significant change. For female, combined time-course and dose-dependency studies was conducted. Thus, the female data of the 7-day treatment in the time-course study are adopted from those of the dose-dependency study. So, data of the control and 3000 ppm groups were repeatedly presented. PROD, 7-pentoxyresorufin O-depentylase; SER, smooth endoplasmic reticulum; ND, not determined. Due to limitation in the availability of the CAR KO rats, only 5 animals per dose could be used. For evaluation of replicative DNA synthesis, we consider that the numbers of animals per dose is sufficient although more optimal numbers would be 8-10 rats per dose. Since small number of animals examined (n ¼ 5) may result in an increased coefficient of variation and decreases the statistical power of the assay a second, experiment using WT rats was conducted.
a For the control group of the first experiment, food consumption was calculated by excluding 2 of 5 animals due to severe diet spillage.
b
For the momfluorothrin group of the first experiment, 2 of 5 animals had severe toxicity as evidenced by marked suppression of body weight with decreased food consumption. When data of these 2 toxic animals are excluded, replicative DNA synthesis is 2.77 6 0.96 (n ¼ 3). This value is 3.1-fold of control and statistically significant (P < .01) compared with control, and is presented in Figure 5C as the data of the first experiment of WT rats.
For histopathology, data represent the number of animals with the lesion/total number of animals examined. Grade of histopathology: 6, relative liver weight was also observed in female rats given 200 ppm momfluorothrin ( Figure 4A ). PROD activity was also statistically significantly increased in both sexes at 1500 and 3000 ppm (except for males at 1500 ppm) ( Figure 4C ). Increased PROD activity in males at 1500 ppm was a marginal change without statistical significance (1.2-fold of control). At 3000 ppm in both sexes, hepatocellular hypertrophy was observed in 2 and 3 of 10 animals in males and females, respectively (Table 2 ). In contrast, male and female rats administered 200 and 500 ppm revealed no treatment related changes in hepatocyte replicative DNA synthesis, hepatocellular hypertrophy and PROD activity. All of the effects on liver weight, hepatocellular hypertrophy and PROD activity observed after 7 days of treatment with momfluorothrin returned to control levels upon cessation of treatment for 7 days ( Table 2 ). The reversibility of the effect of momfluorothrin on hepatocyte replicative the DNA synthesis was not examined.
In Vivo Momfluorothrin Study in WT and CAR KO Rats
The hepatic effects of momfluorothrin were investigated in an in vivo study using a CAR KO rat model, which has only recently become commercially available. Male WT and CAR KO rats were given 0 (control) and 3000 ppm momfluorothrin for 7 days. In addition, the effects of 1800 ppm metofluthrin and 1000 ppm NaPB at, 2 known CAR-mediated MOA liver tumor inducers, were also investigated. The data are presented in Table 3 . In the first experiment with WT rats, 2 of 5 animals treated with momfluorothrin showed severe toxicity due to a palatability problem as evidenced by marked decrease of body weights accompanied by considerable suppression of food consumption. However, there was individual variation of sensitivity to this palatability problem; the other 3 rats showed no such severe toxicities. These toxicities of momfluorothrin were also observed in the second experiment with WT rats and CAR KO rats, but the toxicity was less than those in the first experiment with WT rats.
Under such conditions, NaPB, metofluthrin (except in the first experiment, where a 1.6-fold increase was observed) and momfluorothrin significantly increased CYP2B1/2 mRNA levels in WT rats suggesting CAR functionally responded in WT rats; but not in CAR KO rats, indicating that this CAR KO rat model is reliable (Figs. 5A and B, Table 3 ). Replicative DNA synthesis was evaluated with groups of 5 rats in 2 separate experiments in WT rats. NaPB significantly increased (8.1-fold control) or increased (8.4-fold control) replicative DNA synthesis in the first and second experiments with WT rats, respectively; whereas metofluthrin increased (3.9-fold control) or significantly increased (4.1-fold control) and momfluorothrin significantly increased (3.1-fold control after excluding 2 animals with bad health condition in the first experiment) or increased (8.7-fold control) in the first and second experiments with WT rats, respectively. In contrast to the WT rats, these chemicals did not produce any significant increases in replicative DNA synthesis in the CAR KO rats ( Figure 5C , Table 3 ). Increased liver weights and/or hepatocellular hypertrophy were also observed in WT rats treated with NaPB, metofluthrin or momfluorothrin, while no such effects were observed in the CAR KO rats treated with these chemicals even at similar intakes of test agents between WT and CAR KO rats (Table 3) . Taken together, these data demonstrate that the induction replicative DNA synthesis in rats treated with NaPB, metofluthrin and momfluorothrin is mediated through CAR. When responses to momfluorothrin between Wistar rats (Table 2 ) and SD rats (Table 3 , WT rats in the CAR KO rat study) were compared, both strains responded qualitatively similarly to momfluorothrin, as demonstrated by increases in CYP2B1/2 mRNA levels and replicative DNA synthesis. Quantitatively, the increases in CYP2B1/2 mRNA levels was greater in SD rats, with the increases being 40-fold (mean of 2 experiments with 54-and 25-fold increases) and 18-fold in SD and Wistar rats, respectively. However, for replicative DNA synthesis the response was equivalent in both SD and Wistar rats, the increases being 5.3-(mean of 2 experiments with 1.93-and 8.72-fold increases) and 5.3-fold, respectively. Overall, these findings demonstrate that SD rats are responsive to momfluorothrin and hence that SD CAR KO rats may be employed to evaluate the CAR-dependency of the hepatic effects of momfluorothrin.
Hepatic Global Gene Expression and CYP mRNA Levels
For the global gene expression profile analysis in the liver of male Wistar rats treated with momfluorothrin at 3000 ppm for 14 days, a list of significant alterations in gene expression are shown in Supplementary Table 2. Since this analysis was conducted prior to the present MOA studies, as described in the "Materials and Methods" section, the study conditions were not completely the same as the present MOA studies. However, the data obtained is useful in helping establish the MOA for momfluorothrin-induced liver tumor formation. Numbers of probe sets with 1.5-fold alterations compared with control group were 107 as up-regulation and 268 as down-regulation. Of these, some overlapped with genes altered after 14-day treatment with a CAR activator NaPB (1000 ppm): upregulated gene were Akr7a3, Aldh1a1, Aldh1a4, App, Atpif1, Ces2, Cd14, Cyp2b2/Cyp2b15, Ephx1, Ddc, Gsta2, Gstm1, RGD1562732_predicted, Snx10, Udpgtr2 and Zdhhc2; downregulated genes were Atf5, Eif4g2, C4bpb, Ciapin1, LOC678772, Nrd1, Oat, Spetex-2G, Srebf1 and Zdhhc23. The result of hierarchical clustering analysis showed that the gene expression pattern of the liver from rats treated with momfluorothrin at 3000 ppm was clustered most closely to that of NaPB (Supplementary Figure 1) .
DISCUSSION
MOA Data
Activation of the nuclear CAR (Key event No. 1). CYP2B enzyme induction in rodent liver involves activation of CAR Wei et al., 2000; Yamamoto et al., 2004) . To probe the role of CAR in the MOA for momfluorothrin-induced rat liver tumor formation, the RNAi technique was employed. CARsiRNA was used to reduce CAR mRNA levels in order to examine CAR involvement on the effect of momfluorothrin on CYP2B1/2 mRNA induction in Wistar rat hepatocytes, employing a similar experimental design to that previously used in the metofluthrin study . NaPB was employed as a positive control for these studies. The treatment of Wistar rat hepatocytes with CAR-siRNA significantly reduced CAR mRNA in the Although hepatocyte labeling index values, determined as BrdU labeling index, may return toward control levels with continued momfluorothrin treatment for more than 14 days, the number of cell replications in treated animals appeared to be enhanced due to the increased total number of hepatocytes per animal. In this Table, "Increased cell proliferation" means "Increased total cell proliferation".
Increased PROD activity in males at 1500 ppm was a marginal change without statistical significance (1.2-fold of control).
c Cell proliferation in both sexes at 1500 ppm were determined only after 7 days treatment.
d
The combined incidence of hepatocellular adenoma and carcinoma was increased in male rats given 1500 ppm momfluorothrin, with a nonstatistically significant. As the incidences of hepatocellular adenoma, carcinoma, and combined in males given 1500 ppm momfluorothrin were equivalent to or higher than the maximum incidence of the historical background, 1500 ppm was concluded as tumor inducing dose level.
e
The key/associative events in the CAR KO rat study were determined after 7 days treatment.
presence of either NaPB and momfluorothrin, resulting in a reduction in the magnitude of induction of CYP2B1/2 mRNA levels by both compounds (close to significant, P ¼ .07) (Figs. 2D  and E ). These findings demonstrate that momfluorothrin induces CYP2B1/2 mRNA through CAR in Wistar rat hepatocytes and hence momfluorothrin is a CAR activator. This was also strongly supported by the in vivo study in CAR KO rats; where 3000 ppm momfluorothrin increased CYP2B1/2 mRNA in WT rats but not in CAR KO rats ( Figure 5A , Table 3 ).
Hepatic CYP2B induction (associative event). In Wistar male rats, hepatic CYP2B activity was induced 2.8-fold after 7 days treatment with 3000 ppm of momfluorothrin ( Figure 4C , Table 2 ). A marginal increase in CYP2B activity to 1.2-fold of control was observed in male rats given 1500 ppm momfluorothrin for 7 days (Table 2 ). In addition, hepatic CYP2B1/2 mRNA levels in male rats given 3000 ppm momfluorothrin for 7 or 14 days were robustly increased by 16-or 18-fold, respectively ( Figure 1 , Table 2 ), suggesting that CYP2B mRNA levels would also have been significantly increased . Effect of 1000 ppm NaPB, 1800 ppm metofluthrin and 3000 ppm momfluorothrin on CYP2B1/2 mRNA expression levels (A and B) and replicative DNA synthesis (C) in WT and CAR KO rats. Data are presented as mean values 6 SD (5 animals/group) with 2 experiments being performed in WT rats. For the momfluorothrin group in the first experiment, 2 of 5 animals revealed severe toxicity as evidenced by severe suppression of body weight with decreased food consumption. When data of the 2 toxic animals are excluded, replicative DNA synthesis is 2.77 6 0.96 (n ¼ 3). This value is 3.1-fold of control and statistically significant (P < .01) compared with control, and thus that value is plotted in this figure. Values statistically significant from control are: *P < .05; **P < .01.
at lower doses of momfluorothrin. In females, increases in hepatic CYP2B activity were observed at momfluorothrin dose levels of 1500 and 3000 ppm after 7 days ( Figure 4C , Table 2) and at a dose level of 3000 ppm after 14 days (Table 2) . Another investigation also demonstrated that momfluorothrin could induce CYP2B1/2 mRNA in cultured Wistar rat hepatocytes (Okuda et al., in preparation). In addition to Wistar rats, momfluorothrin also produced an induction of hepatic CYP2B1/ 2 mRNA levels in SD rats (data shown for WT rats in the CAR KO rat study, Table 3 ).
Liver hypertrophy (associative event). Treatment with momfluorothrin resulted in significant increases in liver weights associated with hepatocellular hypertrophy throughout the liver lobule (Table 2 ). In addition, increased smooth endoplasmic reticulum (SER), characteristic of enzyme inducers (Ghadially, 1997) , was observed in liver sections from male and female rats given a high 6000 ppm dose level of momfluorothrin for 13 weeks (ECHA, 2014) .
By transmission electron microscopy, the treatment of male rats with 3000 ppm momfluorothrin for 7 and 14 days did not result in any apparent increase in numbers and size of peroxisomes. This confirms the results of the selected CYP mRNA analysis and the global gene expression studies that momfluorothrin is not PPARa agonist in rat liver ( Figure 1 , Table 2 and Supplementary Figure 1) .
Altered gene expression specific to CAR activation (Key event No. 2).
Activation of CAR in both the mouse and rat results in changes in the expression of a large number of genes involved in phases I and II xenobiotic metabolism, cell proliferation, apoptosis and energy metabolism . Although studies in WT mice and CAR-KO mice have demonstrated that not all genes affected by PB are CAR-dependent, some of genes were only induced in WT mice, suggesting CAR specific genes. The altered genes by momfluorothrin treatment at 3000 ppm for 14 days overlapped with genes altered after 14-day treatment with NaPB as shown in this study (Supplementary Table 2 ). In addition, those by momfluorothrin also overlapped with genes altered after 7-day treatment with a CAR activator metofluthrin (1800 ppm) or NaPB (1000 ppm); ie, CYP, family 2, subfamily b; polypeptide 2 aldehyde dehydrogenase; aldo-keto reductase; UDP-glucuronosyltransferase; glutathione-S-transferase and epoxide hydrolase . Interestingly, CAR specific genes demonstrated by Ueda et al. (2002) , those are also included CYP, family 2, subfamily b; aldehyde dehydrogenase; and glutathione-S-transferase, also overlapped. These findings suggest that momfluorothrin alters gene expression specific to CAR.
Increased cell proliferation (key event no. 3). The treatment of male and female Wistar rats with 1500 and 3000 ppm momfluorothrin for 7 days resulted in significant increases in replicative DNA synthesis ( Figure 4B , Table 2 ). Significant increases in replicative DNA synthesis were also observed in male and female Wistar rats given 3000 ppm momfluorothrin for 14 days (Table 2) . However, the magnitude of the increase in replicative DNA synthesis after 14 days was less marked than that observed after 7 days in both sexes ( Figure 3B , Table 2 ). This finding is consistent with previous studies with other mitogenic rodent liver CAR activators where short-term treatment results in a peak stimulation of hepatocyte labeling index values (Cohen and Arnold, 2011; Elcombe et al., 2014; Lake, 2009; Lake et al., 2015; Yamada et al., 2009) . Although the hepatocyte labeling index returns to control levels with continued treatment with the compound, the overall number of cell replications per animal is increased. This is because treatment with such chemicals causes a sustained increase in liver weight which results in an overall increase in the number and size of hepatocytes (Cohen and Arnold, 2011; Elcombe et al., 2014; Lake, 2009 ). For example, in a study employing a stereological technique, an increase in the total number of hepatocytes per animal was observed in rats treated with PB for 12 weeks (Carthew et al., 1998) . Thus, although hepatocyte labeling index values may return to control levels after continued momfluorothrin treatment, the number of cell replications in treated animals continues to be enhanced due to the increase in the total number of hepatocytes per animal. The continued stimulation of cell proliferation may lead to tumor formation as a result of critical errors being produced during cell replication and/or enhanced proliferation of spontaneously initiated preneoplastic hepatocytes (Cohen and Arnold, 2008; Schulte-Hermann et al., 1983) .
Another investigation also demonstrated that momfluorothrin could increase replicative DNA synthesis in cultured Wistar rat hepatocytes (Okuda et al., in preparation). Furthermore, momfluorothrin increased replicative DNA synthesis in WT rats (Tables 2 and 3 ), but not in CAR KO rats ( Table 3 ), demonstrating that CAR activation is required for momfluorothrin-increased hepatocellular proliferation.
Clonal expansion leading to altered hepatic foci (Key event No. 4). The treatment of male and female Wistar rats with momfluorothrin for 2 years resulted in liver tumor formation. In addition to the formation of liver tumors, the chronic treatment of male and female rats with 3000 ppm momfluorothrin also resulted in significant increases in eosinophilic hepatocellular foci (Table 1) .
Liver adenoma/carcinoma (key event no. 5). The incidences of the total number of animals with hepatocellular adenomas and/or carcinomas of the 0, 200, 500, 1500, and 3000 ppm groups were 2%, 0%, 4%, 12%, and 33% for males, and 0%, 0%, 2%, 2%, and 10% for females, respectively (Table 1) . Treatment with 3000 ppm momfluorothrin significantly increased the incidence of hepatocellular adenoma in both sexes and of hepatocellular carcinoma in male rats. The combined incidence of hepatocellular adenoma and carcinoma was significantly increased in male and female rats given 3000 ppm momfluorothrin, with a nonstatistically significant increase being observed in male rats given 1500 ppm momfluorothrin. Therefore, the incidences of hepatocellular adenoma, carcinoma, and combined in males given 1500 and 3000 ppm momfluorothrin were equivalent to or higher than the maximum incidence of the historical background; and the combined incidence of female rats given 3000 ppm momfluorothrin was within the historical background incidence, while incidence of carcinoma was equivalent to the maximum incidence of the historical background. Overall, treatment with momfluorothrin in rats for 2 years produced hepatocellular tumors in males at 1500 and 3000 ppm and in females at 3000 ppm. The no tumorigenic dose levels (no observed effect levels for tumors) in male and female rats were established at 500 and 1500 ppm, respectively.
Postulated MOA for Momfluorothrin-Induced Rat Liver Tumor Formation Metofluthrin, a close structural analogue to momfluorothrin, also increased hepatocellular tumors in rats. The MOA for tumor formation by metofluthrin in rats was shown to be similar to that of the prototypic CAR activator phenobarbital (Kushida et al., 2016; Yamada et al., 2009 Yamada et al., , 2015 . This MOA involves activation of CAR, which results in a pleiotropic response including the stimulation of CYP2B subfamily enzymes, hepatocellular hypertrophy and increased hepatocellular proliferation. Prolonged treatment results in the formation of altered hepatic foci and liver tumors. Activation of CAR, increased cell proliferation and the development of altered hepatic foci are considered to be key events in the MOA for tumor formation by such compounds as they constitute necessary steps in the MOA . The induction of CYP2B enzymes and liver hypertrophy (both morphological changes and increases in liver weight) are considered as associative events and as such represent reliable markers of CAR activation . Based on a close structural analogue, metofluthrin, the MOA for momfluorothrin-induced rat liver tumor formation is postulated to also involve activation of CAR. The validity of this hypothesis is discussed below.
Concordance of Dose-Response Relationships
This MOA study was performed with momfluorothrin doses used in the 2-year bioassay. As shown in Figure 4 , the effects of momfluorothrin on CYP2B enzyme induction, hypertrophy (liver weight), and cell proliferation (replicative DNA synthesis) showed similar dose-dependency. In particular, in males and females at 3000 ppm, those effects were significantly increased and corresponded with the tumor inducing dose (Table 4 ). In addition to the 7-day study, increases in hepatocyte hypertrophy and relative liver weights were also observed at 1500 ppm and above in both male and female Wistar rats after treatment for 52 weeks or longer (ECHA, 2014) .
In males at 1500 ppm, the increased incidence of liver tumor was equivocal; not statistically significant, but equivalent to or higher than the maximum incidence of the historical background in male Wistar rats. Thus 1500 ppm in males appeared to be borderline for tumor production. The increased relative liver weights and hepatocellular proliferation observed in rats given 1500 ppm momfluorothrin correlated with the observed tumor formation (Table 4 ). The treatment of male Wistar rats with 1500 ppm momfluorothrin did not result in a significant increase in CYP2B enzyme activity ( Figure 4C ), hence the dose response between tumor formation and CYP2B induction was not completely matched (Table 4) . However, there were 16-to 18-fold increases in CYP2B1/2 mRNA levels in male Wistar rats given 3000 ppm momfluorothrin for 7 and 14 days (Table 2) , which suggest that some increase in CYP2B1/2 mRNA levels would have been observed in male rats treated with 1500 ppm momfluorothrin. Moreover, hepatocellular tumor incidence at this dose level was only marginally increased (not statistically significant) and increased incidences of eosinophilic hepatocellular foci were only observed at 3000 ppm in both sexes (Table  1) . The tumor incidence data suggest that the potency for CAR activation by momfluorothrin would be less at a dose level of 1500 ppm than at 3000 ppm. Indeed, the present data demonstrate that the effects on hepatocellular proliferation, CYP2B enzyme induction and liver hypertrophy were less marked in male Wistar rats given 1500 compared with 3000 ppm momfluorothrin (Table 2) .
In females given 1500 ppm momfluorothrin, while the early events such as the increased hepatic CYP2B activity, relative liver weight and hepatocellular proliferation were observed after 7 days of treatment, liver tumor formation was not increased (Table 4) .
Temporal Association
If a key event (or events) is an essential element for carcinogenesis, it must precede the appearance of the tumors. Data are available for the effect of treatment of male and female Wistar rats with momfluorothrin at various time points ranging from 7 days to 2 years (Table 4 ). The treatment of male and female Wistar rats with momfluorothrin for 7 days resulted in an induction of CYP2B enzymes. Cell proliferation, assessed as the hepatocyte labeling index, was increased in male and female Wistar rats given tumorigenic dose levels of momfluorothrin for 7 and 14 days. Momfluorothrin produced increases in liver hypertrophy (assessed both by morphology and as increases in liver weight) at a number of early time points and also at later time points. Examination of liver sections from the momfluorothrin 2-year bioassay revealed increases in altered cell foci at the tumorigenic dose level of 3000 ppm in male and female Wistar rats. In total 3 of 51 male Wistar rats given 1500 ppm momfluorothrin also had altered cell foci ( Table 1) . As altered foci are the precursor lesions for subsequent tumor formation in rodent liver , it is considered that the liver foci developed before the appearance of liver tumors. Overall, there is a logical temporal sequence for all key and associative events in momfluorothrin-induced liver tumor formation, in which all key and associative events precede tumor formation (Table 4) .
In females at 1500 ppm, while the early events such as the increased hepatic CYP2B activity, relative liver weights and hepatocellular proliferation were observed after 7 days of treatment, liver tumor was not increased (Table 4) . Incidence of the eosinophilic hepatocellular foci was observed at 1500 ppm with a nonstatistically significant increase and higher than average but less than highest incidence of historical control (Table 1) . These finding suggest that 1500 ppm momfluorothrin induced the early events but not later events promoting from foci to tumor in female Wistar rats.
Strength, Consistency, and Specificity of Association of Key Events and Tumor Response As mentioned earlier, the effects of momfluorothrin on key and associative events at early phase of treatment correlated with the dose-relationship for liver tumor formation. Furthermore there is a logical temporal sequence for all key and associative events in momfluorothrin-induced liver tumor formation, in which all key and associative events precede tumor formation.
The effects of momfluorothrin on liver weight, hepatocellular hypertrophy and CYP2B enzyme induction after 7 days of treatment were shown to be reversible after 7 days of cessation of treatment. Therefore, effects of short term treatment with momfluorothrin on the liver are reversible, which is consistent with the known hepatic effects of other mitogenic rodent liver CAR activators (LeBaron et al., 2013 (LeBaron et al., , 2014 Osimitz and Lake, 2009; Tinwell et al., 2014; Yamada et al., 2014) .
Biological Plausibility and Coherence
The proposed MOA for liver tumor formation by momfluorothrin involves activation of CAR which results in the key event of increased cell proliferation. Associative events include induction of CYP2B enzymes and liver hypertrophy. Prolonged treatment results in the formation of altered hepatic foci and liver tumors ( Figure 6 ). This MOA is similar to that of several other nongenotoxic rodent liver carcinogenic agents which are CAR activators (Currie et al., 2014; Lake et al., 2015; LeBaron et al., 2013 LeBaron et al., , 2014 Osimitz and Lake, 2009; Tinwell et al., 2014; Yamada et al., 2009 Yamada et al., , 2014 .
As described earlier, the key events for the MOA for momfluorothrin-induced rat liver tumor formation comprise CAR activation, increased cell proliferation and the development of altered hepatic foci as these constitute necessary steps in the MOA. The induction of CYP2B enzymes and liver hypertrophy comprise associative events and represent reliable markers of CAR activation. The role of CAR in CYP2B enzyme induction and increased hepatocellular proliferation by momfluorothrin was also demonstrated in cultured rat hepatocytes using the RNAi technique and in an in vivo study in CAR KO rats. These findings are consistent with the findings with metofluthrin based on previous Yamada et al., 2009) and present MOA studies.
Nongenotoxic chemicals which are activators of CAR may produce liver tumors in both rats and mice (Lake, 2009 ). Generally, the mouse appears to be more susceptible than the rat to liver tumor formation by such compounds. However, not all nongenotoxic CAR activators which produce liver tumors in the rat also produce tumors in the mouse. For example, the natural pyrethrins, which are known to produce liver tumors in the rat through activation of CAR, do not produce liver tumors in the mouse (Osimitz and Lake, 2009 ). Metofluthrin, a close structural analog to momfluorothrin, also increased hepatocellular tumors in Wistar rats through activation of CAR but not in CD-1 mice . Rat specific liver tumor production is not specific to pyrethroids. Metazachlor, a chloroacetanilide herbicide, also produced liver tumors in female Wistar rats but not in CD-1 mice (ECHA, 2011). The CD-1 mouse is not a resistant strain to chemically induced liver tumor formation and is often used to examine the carcinogenicity of nongenotoxic chemicals. Our findings, including unpublished data, suggest that the key and associate events for liver tumor formation by momfluorothrin can occur in both the rat and mouse at early time points. Increases of hepatocellular replicative DNA synthesis, liver weights and CYP2B activity were observed in mice at 7 and 14 days treatment. However, at longer treatment times, these findings in the liver of mice treated with momfluorothrin were less marked than in the rat. We have no direct evidence to explain precisely this species difference, but pharmacokinetic and/or metabolism differences of this compound between rats and mice may be the basis for the species difference in liver tumor production.
Other MOAs
Liver tumors can be produced in rodents by both genotoxic and nongenotoxic agents (Cohen and Arnold, 2011; Williams, 1997) . Momfluorothrin is clearly not genotoxic, being negative in a variety of in vivo and in vitro genotoxicity assays (Ames test, in vitro chromosomal aberration test, in vitro gene mutation assay, unscheduled DNA synthesis assay and mouse micronucleus test) (ECHA, 2014) . Liver tumors can be produced in rodents by various nongenotoxic MOAs including cytotoxicity, activation of CAR, activation of PPARa, porphyria, statins and hormonal perturbation (Cohen, 2010; Cohen and Arnold, 2016; Holsapple et al., 2006; Klaunig et al., 2003; Meek et al., 2003) . In the general toxicity studies, utilizing both histopathology and electron microscopy techniques, there was no evidence of hepatocellular toxicity (eg, necrosis, fatty liver), peroxisome proliferation, porphyria, statin-like alterations, increased iron deposition or any evidence of hormonal perturbation. In addition, as shown in Figure 1 and Supplementary Figure1, unlike effects on CAR, gene expression profiling analysis studies demonstrated no marked alterations in either PPARa, AhR, or pregnane X receptor signaling. Overall, it is considered that the hepatic effects of momfluorothrin in the rat and subsequent liver tumor formation are mediated by activation of CAR. Although some oxidative stress related genes were increased in the global gene expression analysis (Supplementary Table 2) , we have not examined the direct endpoints related to oxidative stress. Oxidative stress in the liver after administration of phenobarbital or metofluthrin was assessed by MDA as an indicator of lipid peroxidation, as well as total and reduced glutathione as a measure of antioxidant capacity. However, no evidence was obtained for the involvement of oxidative stress in phenobarbital or metofluthrin-induced rat liver tumor formation . In the liver of rats treated with momfluorothrin, there was no histopathological evidence indicating increased oxidative stress, such as degenerative findings like necrosis and fibrosis. Though oxidative stress has been implicated as an important factor in the carcinogenesis process for both genotoxic and nongenotoxic mechanisms (Klaunig and Kamendulis, 2004) , it was not identified as a key event for liver tumor formation by phenobarbital and other CAR activators .
Uncertainties, Inconsistencies, and DATA Gaps No data have been obtained for effects of momfluorothrin treatment on apoptosis and inhibition of gap junctional intercellular communication, which were identified as an associative event and an associative event/modulating factor, respectively, in the MOA for phenobarbital-induced rodent liver tumor formation proposed by Elcombe et al. (2014) . We consider that, since decreased apoptosis or inhibition of gap junctional intercellular communication are not key events , these data gaps do not alter the overall conclusion regarding the postulated MOA for momfluorothrin-induced rat liver tumors.
Conclusions: Assessment of Postulated MOA These data are considered adequate with a high degree of confidence to explain the development of liver tumors in rats following chronic administration of momfluorothrin. As described above, the key and associative events in the postulated MOA for momfluorothrin-induced liver tumor formation have been established, with a strong dose-response and temporal consistency. The postulated MOA is similar to that of certain other nongenotoxic mitogenic rodent liver carcinogenic agents which are CAR activators including that of a close structural analogue metofluthrin (Currie et al., 2014; Kushida et al., 2016; Lake et al., 2015; LeBaron et al., 2013 LeBaron et al., , 2014 Osimitz and Lake, 2009; Tinwell et al., 2014; Yamada et al., 2014 Yamada et al., , 2015 . Alternative MOAs for momfluorothrin-induced rat liver tumor formation have been excluded. Additionally, the findings from global gene expression analysis conducted in a separate study strongly support our postulated MOA involving CAR-mediated liver tumor production by momfluorothrin in the present study. This provides evidence that toxicogenomics can provide an initial suggestion for a possible MOA. The human cancer risks of momfluorothrin will be assessed based on the IPCS framework in another publication (Okuda et al., in preparation).
SUPPLEMENTARY DATA
Supplementary data are available at Toxicological Sciences online.
